Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,177.9
-14.8 (-0.46%)

 

  • STI Straits Times Index
    3,177.9
    -14.8 (-0.46%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,685.7
    -16.4 (-0.96%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,001.2
    -4.2 (-0.02%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,576.7
    -3.0 (-0.12%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    20,593.7
    -29.2 (-0.14%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,477.0
    8.4 (0.13%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,124.5
    6.7 (0.32%)
    Index delayed 20 minutes
  • XAO XAO
    5,908.7
    -15.6 (-0.26%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 351.5M
  • Value: 488.6M
  • Rise: 97
  • Fall: 139
  • Unch: 611

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Genting Sing1.080-0.010
Rex Intl0.080+0.001
LionGold0.001-
ThaiBev0.730-0.005
HPH Trust USD0.245-0.010
Ezion0.051-
CapitaMall Trust2.300+0.030
Advance SCT0.001-
DeClout0.130-
Ascendas Reit2.670-0.040

World Indices

World Indices
Name Last Change
Nasdaq 7,020.4 -136.9
HSI 26,988.6 -16.9
HSCEI 10,622.1 +8.6
Jakarta 6,477.0 +8.4
Nikkei 225 20,593.7 -29.2
SSE Comp 2,576.2 -3.5
Shanghai A 2,697.7 -3.7
Shanghai B 276.7 -0.7
ShenZhen A 1,372.2 -2.3
ShenZhen B 862.9 -0.3
Taiwan W 9,846.4 -48.3
PSE Comp 0.0
KOSPI 2,124.8 +7.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Hyphens Pharma HYPHENS PHARMA INTL LIMITED
Quotes 10 Minutes Delayed. Updated at 23 Jan 2019 14:09
Last (SGD): 0.185 Change: -0.005 High: 0.185 Remarks: -
Change (%): -2.63 Low: 0.185
Open 0.185 Yesterday's Close 0.190
Buy Price 0.185 Sell Price 0.190
Buy Volume ('000) 13.5 Sell Volume ('000) 2.1
Cumulative Volume ('000) 2.1 Cumulative Value 389
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a - Trailing EPS (SGD) e - NAV (SGD) b 0.1280
PE a - Trailing PE f - Price / NAV b 1.4453
Dividend (SGD) d - Cash In Hand (SGD) g 0.0776 Issued & Paid-up Shares c 300,000,000
Dividend Yield (%) d - Price / Cash In Hand g 2.384 Treasury Shares h -
Beta - 75 Daysi 0.294 R-Squared - 75 Days(%)i 1.67 Market Cap (M) 55.500
Beta - 500 Daysi 0.348 R-Squared - 500 Days (%)i 1.98 Enterprise Value (M) 34.327
Piotroski F Score - Exchange Code 1J5 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 6-Month VWAP 0.210 Free Float (%) 20.0
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Service - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 15 Nov 2018.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Hyphens Pharma SGX 55.500 - - 1.4453 -
Industry Pharmaceuticals: Major SGX 55.500 - - 1.4453 -
Global Peer JOHNSON & JOHNSON NYSE 345,439.024 265.720 224.020 5.3452 2.578
Global Peer PFIZER INC NYSE 244,340.890 11.469 10.258 3.4270 3.181
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 225,271.642 29.102 16.820 2.8904 2.559
Global Peer MERCK & CO INC NYSE 197,186.815 82.368 58.914 6.0819 2.585
Global Peer ABBVIE INC NYSE 133,364.145 25.244 17.709 -45.6563 3.140
Global Peer LILLY ELI & CO NYSE 124,035.779 - 275.574 9.4853 1.845
Global Peer SANOFI SPON ADS ECH REP 1/2 ORD EUR2 LEVEL II NASDAQ 106,964.539 25.015 27.542 1.6302 2.937
Global Peer NOVO-NORDISK AS ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 96,985.266 16.774 15.452 12.6099 2.304
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 96,732.503 49.029 38.894 16.5724 5.403
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 91,762.012 30.253 37.632 7.6879 3.781
Other Global Peers BRISTOL-MYERS SQUIBB CO (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), CHINARES PHARMA (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), INNOVENT BIO-B (HKEx), HUTCHISON CHINA MEDITECH SPON ADR EACH REPR 0.50 ORD SHS (NASDAQ), AKCEA THERAPEUTICS INC (NASDAQ), CMS (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), JUNSHI BIO-B (HKEx), ALLAKOS INC (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), CHINAGRANDPHARM (HKEx), PHIBRO ANIMAL HEALTH CORP (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), HUA MEDICINE-B (HKEx), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), TRICIDA INC (NASDAQ), UNITED LAB (HKEx), RA PHARMACEUTICALS INC (NASDAQ), PETIQ INC (NASDAQ), ATHENEX INC (NASDAQ), PRINCIPIA BIOPHARMA INC (NASDAQ), AC IMMUNE SA (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), OBSEVA SA (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ZYMEWORKS INC (NYSE), CLEMENTIA PHARMACEUTICALS INC (NASDAQ), NIGHTSTAR THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), AKORN INC (NASDAQ), ODONATE THERAPEUTICS LLC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), EVOLUS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), GRITSTONE ONCOLOGY INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), FORTY SEVEN INC (NASDAQ), IGBB (Bursa), NC HEALTHCARE (HKEx), BEYONDSPRING INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), DAWNRAYS PHARMA (HKEx), EVELO BIOSCIENCES INC (NASDAQ), LANNETT CO INC (NYSE), UROVANT SCIENCES LTD (NASDAQ), THE FS ALSEC ALPHASECTOR (NASDAQ), GAMIDA CELL LTD (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), FUSEN PHARM (HKEx), TYME TECHNOLOGIES INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), DOVA PHARMACEUTICALS INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), Phapros Tbk. (IDX), AERPIO PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), AFT PHARMACEUTICALS LTD (ASX), AGEX THERAPEUTICS INC (NYSE American), MENLO THERAPEUTICS INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), ZOMEDICA PHARMACEUTICALS CORP (NYSE American), TELIGENT INC NEW (NASDAQ), CHARMACY PHAR (HKEx), PHASEBIO PHARMACEUTICALS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), NEP INTERLONG (HKEx), TPI ENTERPRISES LIMITED (ASX), ARIDIS PHARMACEUTICAL INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), SIENNA BIOPHARMACEUTICALS INC (NASDAQ), KOTRA (Bursa), MEDLAB CLINICAL LIMITED (ASX), ARCTURUS THERAPEUTICS LTD (NASDAQ), CRESO PHARMA LTD (ASX), SINOLIFE UTD (HKEx), BIOHLDG (Bursa), MMJ GROUP HOLDINGS LTD (ASX), ENTERA BIO LTD (NASDAQ), NOVAN INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), NOXOPHARM LTD (ASX), NOVA (Bursa), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), EYENOVIA INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), EXOPHARM LTD (ASX), NOVUS THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), ESSA PHARMA INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), GEMPHIRE THERAPEUTICS INC (NASDAQ), FARMAFORCE LTD (ASX), RECCE PHARMACEUTICALS LTD (ASX), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), RACE ONCOLOGY LTD (ASX), FIJI KAVA LTD (ASX), Merck Sharp Dohme Pharma Tbk. (IDX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.005
-2.63 %
10 Days --0.004
-2.12 %
20 Days --0.010
-5.13 %
Medium Term Return 3 Months --0.030
-13.95 %
6 Months --0.035
-15.91 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.180 - 0.305 Change From 1 Year Low +0.005 % Change From 1 Year Low (%) +2.78
Change From 1 Year High -0.120 % Change From 1 Year High (%) -39.34
2 Years Range 0.180 - 0.305 Change From 2 Years Low +0.005 % Change From 2 Years Low (%) +2.78
Change From 2 Years High -0.120 % Change From 2 Years High (%) -39.34
5 Years Range 0.180 - 0.305 Change From 5 Years Low +0.005 % Change From 5 Years Low (%) +2.78
Change From 5 Years High -0.120 % Change From 5 Years High (%) -39.34
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapore’s leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Group’s regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.

The Group’s core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

IPO Performance

Listing Date 18 May 2018 Full Subscription Rate (x) 17.91
No of Placement Shares (M) 23.79 No of Public Offer Shares (M) 3.00 Public Offer Subscription Rate (x) 151.99
IPO Price (SGD) a 0.260 First Day Close (SGD) a 0.275 First Week Close (SGD) a 0.260
Current vs IPO Price (%) -28.85 First Day Gain (%) +5.77 First Week Gain (%) -
Notes:
  1. Adjusted for the following: 23,790,000 Placement Shares do not include the 2,810,000 Reserved Shares.

Reports Download

Report Type Financial Year Ended Download
IPO Prospectus
IPO Prospectus 2018 May 2018 Part 1(2.57 MB)
Part 2(0.27 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
22 Jan 2019 0.190 0.190 0.190 0.190 - -
21 Jan 2019 0.190 0.190 0.190 0.190 14,200 0.1900
18 Jan 2019 0.190 0.190 0.190 0.190 30,000 0.1900
17 Jan 2019 0.190 0.190 0.190 0.190 - -
16 Jan 2019 0.190 0.190 0.190 0.190 - -
15 Jan 2019 0.190 0.190 0.190 0.190 - -
14 Jan 2019 0.190 0.190 0.190 0.190 - -
11 Jan 2019 0.190 0.190 0.190 0.190 100,000 0.1900
10 Jan 2019 0.190 0.190 0.190 0.190 - -
09 Jan 2019 0.190 0.190 0.190 0.190 57,000 0.1900
08 Jan 2019 0.184 0.189 0.184 0.189 18,100 0.1884
07 Jan 2019 0.182 0.182 0.182 0.182 8,500 0.1820
04 Jan 2019 0.180 0.180 0.180 0.180 5,000 0.1800
03 Jan 2019 0.195 0.195 0.181 0.181 4,000 0.1922
02 Jan 2019 0.195 0.195 0.195 0.195 - -
31 Dec 2018 0.194 0.195 0.194 0.195 9,500 0.1948
28 Dec 2018 0.195 0.195 0.195 0.195 - -
27 Dec 2018 0.195 0.195 0.195 0.195 - -
26 Dec 2018 0.195 0.195 0.195 0.195 - -
24 Dec 2018 0.190 0.195 0.190 0.195 11,000 0.1905
21 Dec 2018 0.190 0.190 0.190 0.190 20,000 0.1900
20 Dec 2018 0.190 0.190 0.190 0.190 400 0.1900
Summary
Current 2 Weeks
(09 Jan 2019 to 22 Jan 2019)
0.190 0.190 0.190 0.190 201,200 -
Previous 2 Weeks
(24 Dec 2018 to 08 Jan 2019)
0.190 0.195 0.190 0.189 56,100 -
4 Weeks from
(26 Nov 2018 to 21 Dec 2018)
0.200 0.200 0.190 0.190 95,700 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.